Clobetasol foam effective; may be preferred to creams, ointments
Washington - Clobetasol delivered in a foam vehicle is associated with significant improvement of hand dermatitis and appears to be preferred by patients over other vehicles, leading to a high rate of compliance, said J. Mark Jackson, M.D., assistant clinical professor of medicine and dermatology, division of dermatology, University of Louisville.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.